Raf1, Aurora-A/STKI 5 and E-cadherin biomarkers expression in patients with pTa1pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up

被引:33
作者
Mhawech-Fauceglia, P.
Fischer, G.
Beck, A.
Cheney, R. T.
Herrmann, F. R.
机构
[1] Roswell Pk Canc Inst, Dept Pathol & Lab Med, Buffalo, NY 14263 USA
[2] Univ Hosp Geneva, Dept Rehabil & Geriatr, Geneva, Switzerland
来源
EJSO | 2006年 / 32卷 / 04期
关键词
raft; Aurora-A; E-CD; protein immunohistochemical expression; pTa/pT1 tumour behavior;
D O I
10.1016/j.ejso.2006.01.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: The study was designed to evaluate Raf1, Aurora-A/STK15 and E-cadherin (E-CD) protein expression and their prognostic value in patients with pTa/pT1 tumours. Materials and methods: A tissue microarray of 105 pTa, and 141 pT1 tumours was constructed and sections were immunostained with these three antibodies. Results: There were significant associations between Raf1 overexpression and tumour grade (p=0.03), between Aurora-A overexpression/alterations of E-CD and tumour grade and stage (p<0.001 and p<0.001). In multiple Cox regression analysis, moderate/strong expression of E-CD seemed to be an independent factor in predicting slower tumour progression (p = 0.003) and Aurora-A overexpression (p=0.022) displays an independent value in predicting tumour recurrences. Conclusion: Evaluation of E-CD and Aurora-A expressions in tissue of patients with pTa/pT1 UC have been proven to be useful in predicting tumours behavior and Raf1 protein expression seemed to have no potential use in this regard. (C) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:439 / 444
页数:6
相关论文
共 29 条
[1]   Second nature: Biological functions of the raf-1 "kinase" [J].
Baccarini, M .
FEBS LETTERS, 2005, 579 (15) :3271-3277
[2]   Bladder cancer [J].
Borden, LS ;
Clark, PE ;
Hall, MC .
CURRENT OPINION IN ONCOLOGY, 2005, 17 (03) :275-280
[3]   E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup [J].
Byrne, RA ;
Shariat, SF ;
Brown, R ;
Kattan, MW ;
Morton, RA ;
Wheeler, TM ;
Lerner, SP .
JOURNAL OF UROLOGY, 2001, 165 (05) :1473-1479
[4]  
Fraizer GC, 2004, INT J ONCOL, V25, P1631
[5]   T cell development: Some cells get all the breaks [J].
Green, DR ;
Schuler, M .
NATURE IMMUNOLOGY, 2000, 1 (01) :15-17
[6]   Recurrence and progression in low grade papillary urothelial tumors [J].
Holmäng, S ;
Hedelin, H ;
Anderström, C ;
Holmberg, E ;
Busch, C ;
Johansson, SL .
JOURNAL OF UROLOGY, 1999, 162 (03) :702-707
[7]  
Hoque A, 2003, CANCER EPIDEM BIOMAR, V12, P1518
[8]   High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization [J].
Hurst, CD ;
Fiegler, H ;
Carr, P ;
Williams, S ;
Carter, NP ;
Knowles, MA .
ONCOGENE, 2004, 23 (12) :2250-2263
[9]   Dominant role of E-cadherin in the progression of bladder cancer [J].
Imao, T ;
Koshida, K ;
Endo, Y ;
Uchibayashi, T ;
Sasaki, T ;
Namiki, M .
JOURNAL OF UROLOGY, 1999, 161 (02) :692-698
[10]   Overexpression and amplification of Aurora-A in hepatocellular carcinoma [J].
Jeng, YM ;
Peng, SY ;
Lin, CY ;
Hsu, HC .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :2065-2071